Emerging therapies in castrate-resistant prostate cancer

Current Urology Reports

Volumn 11, Issue 3, 2010, Pages 152-158

  Zarour, Luai ^a   Alumkal, Joshi ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Castration resistant; Prostate cancer

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; ABIRATERONE ACETATE; ANTIANDROGEN; BICALUTAMIDE; BSI 201; CANCER VACCINE; CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IPILIMUMAB; MDV 3100; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN EXPRESSING VACCINIA VIRUS VACCINE; PROVENGE; RAPAMYCIN; SEX HORMONE ANTAGONIST; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ANDROGEN; LYASE;

ADRENAL INSUFFICIENCY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COLITIS; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEVER; HEPATITIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; KIDNEY CARCINOMA; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; REVIEW; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT FAILURE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; MALE; METABOLISM; ORCHIECTOMY; PREVALENCE; PROCEDURES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ANDROGEN ANTAGONISTS; ANDROGENS; CANCER VACCINES; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYASES; MALE; ORCHIECTOMY; PREVALENCE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 77952233948     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-010-0104-x     Document Type: Review

References (50)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. JL Mohler CW Gregory OH Ford 3rd, et al. 2004 The androgen axis in recurrent prostate cancer Clin Cancer Res 10 440 448 10.1158/1078-0432.CCR-1146- 03 14760063 1:CAS:528:DC%2BD2cXovVGktA%3D%3D (Pubitemid 38173980)
3. EA Mostaghel ST Page DW Lin, et al. 2007 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res 67 5033 5041 10.1158/0008-5472.CAN-06-3332 17510436 1:CAS:528:DC%2BD2sXltl2gtrY%3D (Pubitemid 46910214)
4. ME Taplin 2007 Drug insight: role of the androgen receptor in the development and progression of prostate cancer Nat Clin Pract Oncol 4 236 244 10.1038/ncponc0765 17392714 1:CAS:528:DC%2BD2sXjs12rsLY%3D (Pubitemid 46510533)
5. MA Eisenberger R Simon PJ O'Dwyer, et al. 1985 A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma J. Clin Oncol 3 827 841 2409240 1:STN:280:DyaL2M3js1Cnsw%3D%3D
6. PW Kantoff S Halabi M Conaway, et al. 1999 Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 2506 2513 10561316 1:CAS:528:DyaK1MXltlyltL8%3D (Pubitemid 29368252)
7. IF Tannock D Osoba MR Stockler, et al. 1996 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1756 1764 8656243 1:CAS:528:DyaK28XjslOrsr8%3D (Pubitemid 26185452)
8. DP Petrylak CM Tangen MH Hussain, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513 1520 10.1056/NEJMoa041318 15470214 1:CAS:528:DC%2BD2cXot1Kmu7c%3D (Pubitemid 39315318)
9. IF Tannock R de Wit WR Berry, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502 1512 10.1056/NEJMoa040720 15470213 1:CAS:528:DC%2BD2cXot1Kmu7s%3D (Pubitemid 39315317)
10. JE Rosenberg VK Weinberg WK Kelly, et al. 2007 Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 556 563 10.1002/cncr.22811 17577218 1:CAS:528:DC%2BD2sXpt1yqu7o%3D (Pubitemid 47106144)
11. GA Potter SE Barrie M Jarman MG Rowlands 1995 Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer J Med Chem 38 2463 2471 10.1021/jm00013a022 7608911 1:CAS:528:DyaK2MXmtVyisbg%3D
12. G Attard AH Reid R A'Hern, et al. 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742 3748 10.1200/JCO.2008.20.0642 19470933 1:CAS:528:DC%2BD1MXhtFaitr3I This report describes a phase I/II clinical trial with abiraterone acetate in CRPC
13. DC Danila JD Bono CJ Ryan, et al. 2009 Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): impact of prior ketoconazole (keto) J. Clin Oncol 27 15s 10.1200/JCO.2008.21.7695
14. AH Reid G Attard D Danila, et al. 2009 A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695
15. Efstathiou E, Wen S, Molina A, et al.: Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). In 2009 Genitourinary Cancers Symposium.
16. C Tran S Ouk NJ Clegg, et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 787 790 10.1126/science.1168175 19359544 1:CAS:528:DC%2BD1MXlsVeksro%3D This report describes the preclinical findings with MDV3100 in prostate cancer model systems and summarizes some of the clinical findings from the recently completed phase I trial in CRPC
17. HI Scher TM Beer CS Higano, et al. 2009 Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.2092
18. AA Lane BA Chabner 2009 Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 5459 5468 10.1200/JCO.2009.22.1291 19826124 1:CAS:528: DC%2BD1MXhsFKkt7vE
19. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39 10.1182/blood-2006-06-025999 16960145 1:CAS:528:DC%2BD2sXivVyrt7g%3D (Pubitemid 46053039)
20. L Chen S Meng H Wang, et al. 2005 Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 Mol Cancer Ther 4 1311 1319 10.1158/1535-7163.MCT-04-0287 16170022 1:CAS:528: DC%2BD2MXhtVKnt7jL
21. A Gibbs J Schwartzman V Deng J Alumkal 2009 Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6 Proc Natl Acad Sci U S A 106 16663 16668 10.1073/pnas.0908908106 19805354
22. DL Marrocco WD Tilley T Bianco-Miotto, et al. 2007 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol Cancer Ther 6 51 60 10.1158/1535-7163.MCT-06-0144 17218635 1:CAS:528:DC%2BD2sXmsVarsw%3D%3D (Pubitemid 46209918)
23. Bradley DA, Dunn R, Rathkopf D, et al.: Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. In 2008 Genitourinary Cancers Symposium.
24. Hussain M, Dunn R, Rathkopf D, et al.: Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): a phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862). J Clin Oncol 2007, 27:13:2278-2287.
25. C Parker R Molife V Karavasilis, et al. 2007 Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC) J Clin Oncol 25 18s
26. DE Rathkopf KN Chi U Vaishampayan, et al. 2009 Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695
27. JF Gera IK Mellinghoff Y Shi, et al. 2004 AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 279 2737 2746 10.1074/jbc.M309999200 14576155 1:CAS:528:DC%2BD2cXkslyjsw%3D%3D (Pubitemid 38114263)
28. A Di Cristofano B Pesce C Cordon-Cardo PP Pandolfi 1998 Pten is essential for embryonic development and tumour suppression Nat Genet 19 348 355 10.1038/1235 9697695 (Pubitemid 28357906)
29. ME McMenamin P Soung S Perera, et al. 1999 Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage Cancer Res 59 4291 4296 10485474 1:CAS:528:DyaK1MXlvVSms70%3D (Pubitemid 29418745)
30. MS Neshat IK Mellinghoff C Tran, et al. 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 10314 10319 10.1073/pnas.171076798 11504908 1:CAS:528:DC%2BD3MXmvFWiurk%3D (Pubitemid 32803017)
31. F Meric-Bernstam AM Gonzalez-Angulo 2009 Targeting the mTOR signaling network for cancer therapy J Clin Oncol 27 2278 2287 10.1200/JCO.2008.20.0766 19332717 1:CAS:528:DC%2BD1MXlvFOgs7k%3D
32. George DJ, Armstrong AJ, Creel P, et al.: A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC). In 2008 Genitourinary Cancers Symposium.
33. Ross R, Manola J, Oh W, et al.: Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008, 26.
34. AJ Wagner DHV Hoff PM LoRusso, et al. 2009 A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors J. Clin Oncol 27 15s 10.1200/JCO.2008.18.5918 1:CAS:528:DC%2BD1MXktFKhsbw%3D
35. NJ Curtin 2005 PARP inhibitors for cancer therapy Expert Rev Mol Med 7 1 20 10.1017/S146239940500904X 15836799 (Pubitemid 43118235)
36. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 361 123 134 10.1056/NEJMoa0900212 19553641 1:CAS:528:DC%2BD1MXosVKrtrw%3D This report describes the clinical experience from a clinical trial with the PARP inhibitor olaparib
37. HE Bryant N Schultz HD Thomas, et al. 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 10.1038/nature03443 15829966 1:CAS:528:DC%2BD2MXjtFOmsrY%3D (Pubitemid 40559005)
38. H Farmer N McCabe CJ Lord, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 10.1038/nature03445 15829967 1:CAS:528:DC%2BD2MXjtFOmsrc%3D (Pubitemid 40559006)
39. J O'Shaughnessy C Osborne J Pippen, et al. 2009 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial J Clin Oncol 27 18s 10.1200/JCO.2009.22.4626
40. RA Madan PM Arlen M Mohebtash, et al. 2009 Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer Expert Opin Investig Drugs 18 1001 1011 10.1517/13543780902997928 19548854 1:CAS:528:DC%2BD1MXns1erurs%3D
41. PW Kantoff LM Glode SI Tannenbaum, et al. 2006 Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC) J Clin Oncol 24 18s 10.1200/JCO.2006.06.1143
42. Kantoff PW, Schuetz T, Blumenstein BA, et al.: Overall survival analysis of a phase II randomized controlled trial of a poxviral based PSA targeted immunotherapy in metastatic castration resistant prostate cancer In 2009 ASCO Annual Meeting.
43. Antonarakis ES, Carducci MA, Eisenberger MA: Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 Aug 28 (Epub ahead of print).
44. EJ Small P Fratesi DM Reese, et al. 2000 Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 3894 3903 11099318 1:CAS:528:DC%2BD3cXptVSiurc%3D
45. EJ Small PF Schellhammer CS Higano, et al. 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 3089 3094 10.1200/JCO.2005.04.5252 16809734 1:CAS:528:DC%2BD28XnslKhs7g%3D (Pubitemid 46638945)
46. Dendreon, Inc.: Summary of phase 3 IMPACT trial results. Presented at AUA Meeting 2009.
47. CA Chambers MS Kuhns JG Egen JP Allison 2001 CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 19 565 594 10.1146/annurev.immunol.19.1.565 11244047 1:CAS:528:DC%2BD3MXivFKgurc%3D (Pubitemid 32368046)
48. E Small C Higano N Tchekmedyian, et al. 2006 Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer J Clin Oncol 24 18s 10.1200/JCO.2005.04.5252 1:CAS:528:DC%2BD28XnslKhs7g%3D (Pubitemid 46638945)
49. Beer TM, Slovin SF, Higano CS, et al.: Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008, 26.
50. SF Slovin TM Beer CS Higano, et al. 2009 Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695